Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Menoufia Univ. CDK2 compound 14c
- Development stage
- Unknown
- Lead developer
- Menoufia University
01
Overview
Menoufia Univ. CDK2 compound 14c: sourced facts only. name: "Mechanistic validation confirmed 14c as a superior CDK2 inhibitor (IC50 = 0.21 μM, ∼2-fold more potent than roscovitine) with excellent kinase selectivity (S10 = 0.13)." [PMID:40907441]; target: "Mechanistic validation confirmed 14c as a superior CDK2 inhibitor (IC50 = 0.21 μM, ∼2-fold more potent than roscovitine) with excellent kinase selectivity (S10 = 0.13)." [PMID:40907441]; developer: "Chemistry Department, Faculty of Science, Menoufia University, Shebin El-Koam 32511, Egypt." [PMID:40907441]
02
Targets
CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on Menoufia Univ. CDK2 compound 14c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Menoufia Univ. CDK2 compound 14c.